Atrial Fibrillation & SVT: Adenosine, Rate vs Rhythm
A young woman's heart suddenly races to 180 beats a minute. The doctor pushes a drug that makes her heart briefly STOP on the monitor — a flat line for a few terrifying seconds — and then it restarts in a normal rhythm. That drug, adenosine, lasts only seconds and is blocked by your morning coffee. Then there's atrial fibrillation, the world's commonest arrhythmia, where the real danger isn't the racing heart at all — it's a stroke.
A young woman arrives with a heart suddenly pounding at 180 — a supraventricular tachycardia, a rhythm looping too fast through the heart's upper circuits. Vagal manoeuvres (bearing down, a cold splash) don't break it, so the doctor rapidly injects adenosine and flushes it in. On the monitor, her heart pauses — a stretch of flat line — and she feels a wave of chest tightness and dread. Then, a few seconds later, her heart resumes at a calm, normal rhythm. It's one of the most dramatic moments in medicine, and it teaches how we terminate a fast rhythm and, separately, how we manage the commonest arrhythmia of all.
Adenosine: the reset button
Adenosine briefly blocks the AV node. Many supraventricular tachycardias are a self-perpetuating loop that runs through the AV node. Adenosine works by transiently blocking that node — for a few seconds it stops conduction, which interrupts the loop and lets the heart's normal pacemaker retake control. It has an ultra-short half-life (about ten seconds), so it's given as a rapid push followed by a fast flush. Patients feel a brief but intense chest tightness, flushing, and a sense of impending doom as the heart pauses — alarming but harmless, and over in seconds. A neat pharmacology detail: because caffeine blocks adenosine receptors (from the CNS stimulants article), heavy caffeine can blunt adenosine's effect, while the drug dipyridamole potentiates it.
Atrial fibrillation: two decisions
Atrial fibrillation (AF) is chaotic, disorganized electrical activity in the atria, producing an irregular and often fast heartbeat. Managing it comes down to two separate decisions. First, controlling the heartbeat: you can either control the RATE — using AV-node slowers (beta blockers, verapamil/diltiazem, or digoxin) to keep the ventricles from beating too fast — or restore the RHYTHM back to normal, by cardioversion (an electrical shock or drugs like flecainide or amiodarone) and sometimes catheter ablation. For many patients, rate and rhythm control give similar outcomes, so the choice is individualized. Second, and often more important: preventing stroke.
In atrial fibrillation, the racing heart isn't the real killer — the stroke is. Because the fibrillating atria don't empty properly, blood pools and clots inside them, and a clot can break loose and travel to the brain. So a central part of AF care is assessing stroke risk (with a score called CHA₂DS₂-VASc) and, if it's high enough, starting a blood thinner (an anticoagulant — a DOAC or warfarin, from the antithrombotics section) to prevent that clot. Controlling the rate makes the patient feel better; anticoagulation is what keeps them alive and stroke-free.
- Adenosine transiently blocks the AV node to terminate many SVTs; ultra-short (~seconds).
- It causes brief flushing, chest tightness & a sense of doom; caffeine blunts it, dipyridamole potentiates it.
- AF: choose rate control (AV-node slowers) or rhythm control (cardioversion/ablation).
- The real danger in AF is stroke from atrial clots — assess risk (CHA₂DS₂-VASc) and anticoagulate.
- Controlling the AF rate but forgetting stroke prevention. Anticoagulation is often the key step.
- Giving adenosine slowly. Its ~10-second half-life means it must be a rapid push with a flush.
- Not warning the patient about the alarming (but brief and safe) adenosine sensation.
- Assuming rhythm control is always better than rate control. Outcomes are often similar.
In atrial fibrillation, what is usually the most important step to prevent a catastrophic outcome?
- Adenosine transiently blocks the AV node to terminate many SVTs — ultra-short-acting.
- AF management: rate control (AV-node slowers) or rhythm control (cardioversion/ablation).
- The main danger in AF is stroke from atrial clots — assess risk and anticoagulate.
- Caffeine (adenosine blocker) blunts adenosine; dipyridamole potentiates it.
- Katzung BG. Basic & Clinical Pharmacology — Agents Used in Cardiac Arrhythmias (adenosine; AF management).
- ACC/AHA & ESC Atrial Fibrillation Guidelines — Rate vs rhythm control & anticoagulation.
- Brunton LL, et al. Goodman & Gilman's The Pharmacological Basis of Therapeutics — Antiarrhythmic drugs; adenosine.
- Rang HP, Dale MM, et al. Rang & Dale's Pharmacology — Antidysrhythmic drugs.
- Whalen K. Lippincott Illustrated Reviews: Pharmacology — Antiarrhythmic drugs; adenosine.
